– March 1, 2011
March 1, 2011
View Issues
-
Treating High-risk Prostate Cancer in an 84-Year-Old Man
A 84-year-old retired professor was referred for second opinion regarding management of prostate cancer. He had been relatively healthy, with a history of hyperlipidemia and gout. -
Rasburicase: Clearing Uric Acid from the Tumor Lysis Syndrome
Uric acid as a weak organic acid (pka 5.8) is poorly soluble at physiological pH. -
Cormorbid Disease May Refine MDS Outcomes
Myelodysplastic syndromes (MDS) usually occur in older adults and, as such, comorbid conditions are common. The investigators found that among 418 MDS patients, at least one comorbid condition existed in 93% at diagnosis. Comorbidity scores were generated using three common scoring systems: the HCT-CI, MDS-CI, and CCI. Worse survival was linked to higher CCI (p = 0.01) and MDS-CI (p = 0.02) but not HCT-CI. Higher CCI scores were associated with non-leukemic death and progression of red blood cell dependency, whereas higher comorbidity by HCT-CI and MDS-CI did not. Higher comorbid burden by CCI in MDS predicts for worse survival and non-leukemic death. Comorbidity data may help refine prognosis for MDS patients. -
Treatment of AML and MDS in Older Adults
The prognosis of older adults with AML even after intensive chemotherapy is poor. Kantarjian and colleagues evaluated 446 AML patients 70 years and older who underwent cytarabine-based intensive chemotherapy between 1900 and 2008. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
Escitalopram for menopausal hot flashes, rifaximin for IBS without constipation, herpes zoster vaccination, antiepileptics drugs and fracture risk, and FDA Actions.